Coherus Oncology Inc. (CHRS) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, CHRS scores 36/100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 4/20 (ROIC of -35% and FCF yield of 0%); Whale 13F Flow scores 7/20 (institutional accumulation and options positioning); Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 10/20 (Beta of 1.0 and sector sensitivity); and Forensic Balance Sheet scores 10/20 (Altman Z of 2.5, Piotroski F of 3/9, Debt/Equity of 0.5).

For a prospective investor, the weakest pillar is the cash engine, which signals that the business is not currently generating a return on invested capital or free cash flow. The forensic balance sheet and macro fit pillars are mid-range, meaning the company is not in acute distress by the Altman measure but lacks strong quality signals. Flow and insider pillars are also weak, indicating limited conviction signals from institutional or insider positioning in the source data. Upside drivers in this framework would need to come from a material change in the cash engine; valuation tradeoffs are severe because the equity trades at a market capitalization of $138.8M with no earnings-based multiples available. The rating is analytical and educational, not personalized advice.

Per the SEC financials, reported revenue is $0.0M across all three periods, and operating income is negative in each. Net income is $168.0M in FY 2025 and $28.5M in FY 2024, while FY 2023 shows $-237.9M. Operating, gross, and net margins are each 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9. Debt/Equity is 0.5. Cash was $88.9M at FY 2025 versus $126.0M at FY 2024.

Per the recent news feed, the headlines are dominated by market-wire coverage of CHRS, including a YELLOW-flagged report on the stock price and institutional positioning and a YELLOW-flagged item on potential negative earnings next week. A GuruFocus report describes Phase 1b results in esophageal cancer as promising. A Seeking Alpha report describes early-stage data on tagmokitug in esophageal cancer as promising. A kalkine.ca report notes a 22% drop after the tagmokitug data and is the only item flagged RED under RISK WATCH. A MarketBeat report covers institutional ownership. Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, there are no upstream or downstream links and no proprietary signals recorded. Sector is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances). Not available in source data for supplier, customer, or sector-correlation dependencies beyond this classification. Second-order bottlenecks cannot be mapped from the source data.

• What is the company's revenue base, given reported revenue of $0.0M across all periods?
• What drove the FY 2025 net income of $168.0M against operating losses of $-181.1M, and is that recurring?
• What is the current debt position, given debt is listed as N/A for every period?
• What are the clinical and regulatory milestones behind the esophageal cancer data, and what is the cash runway?
• Why are analyst and holder data unavailable, and what does the absence of institutional coverage imply?